{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:07:49Z","timestamp":1790636869522,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40292-018-0277-9","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T23:41:16Z","timestamp":1537227676000},"page":"355-359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation"],"prefix":"10.1007","volume":"25","author":[{"given":"Arrigo F. G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilisa","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"issue":"1","key":"277_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","volume":"118","author":"M Budoff","year":"2016","unstructured":"Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118(1):138\u201345. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2016.04.004\n                    \n                  .","journal-title":"Am J Cardiol."},{"issue":"4","key":"277_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","volume":"10","author":"KC Maki","year":"2016","unstructured":"Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol. 2016;10(4):905\u201314. \n                    https:\/\/doi.org\/10.1016\/j.jacl.2016.03.008\n                    \n                  .","journal-title":"J Clin Lipidol."},{"key":"277_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner \u017d, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC\/EAS Guidelines for the Management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis. 2016;253:281\u2013344. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.018\n                    \n                  .","journal-title":"Atherosclerosis."},{"issue":"3","key":"277_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1440-1681.12053","volume":"40","author":"Q Geng","year":"2013","unstructured":"Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol. 2013;40(3):219\u201326. \n                    https:\/\/doi.org\/10.1111\/1440-1681.12053\n                    \n                  .","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"277_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.phrs.2015.09.012","volume":"102","author":"G Derosa","year":"2015","unstructured":"Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63\u201370. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2015.09.012\n                    \n                  .","journal-title":"Pharmacol Res."},{"key":"277_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.phrs.2016.06.011","volume":"111","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Giua R, Pedone C, Ray KK, Vallejo-Vaz AJ, Costanzo L. Fibrate therapy and flow-mediated dilation: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2016;111:163\u201379. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2016.06.011\n                    \n                  .","journal-title":"Pharmacol Res."},{"key":"277_CR7","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B\u00f6hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryd\u00e9n L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159\u2013219. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/eht151\n                    \n                  .","journal-title":"Eur Heart J"},{"key":"277_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12986-017-0214-2","volume":"14","author":"AF Cicero","year":"2017","unstructured":"Cicero AF, Fogacci F, Rosticci M, Parini A, Giovannini M, Veronesi M, D\u2019Addato S, Borghi C. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab. 2017;14:61. \n                    https:\/\/doi.org\/10.1186\/s12986-017-0214-2\n                    \n                  .","journal-title":"Nutr Metab."},{"issue":"3","key":"277_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40292-017-0206-3","volume":"24","author":"AF Cicero","year":"2017","unstructured":"Cicero AF, Fogacci F, Morbini M, Colletti A, Bove M, Veronesi M, Giovannini M, Borghi C. Nutraceutical effects on glucose and lipid metabolism in patients with impaired fasting glucose: a pilot, double-blind, placebo-controlled, randomized clinical trial on a combined product. High Blood Press Cardiovasc Prev. 2017;24(3):283\u20138. \n                    https:\/\/doi.org\/10.1007\/s40292-017-0206-3\n                    \n                  .","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"10","key":"277_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/13543784.17.10.1599","volume":"17","author":"T Filippatos","year":"2008","unstructured":"Filippatos T, Milionis HJ. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin Investig Drugs. 2008;17(10):1599\u2013614. \n                    https:\/\/doi.org\/10.1517\/13543784.17.10.1599\n                    \n                  .","journal-title":"Expert Opin Investig Drugs."},{"issue":"7","key":"277_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5551\/jat.39446","volume":"24","author":"A Shinnakasu","year":"2017","unstructured":"Shinnakasu A, Yamamoto K, Kurano M, Arimura H, Arimura A, Kikuti A, Hashiguchi H, Deguchi T, Nishio Y. The combination therapy of fenofibrate and ezetimibe improved lipid profile and vascular function compared with statins in patients with type 2 diabetes. J Atheroscler Thromb. 2017;24(7):735\u201348. \n                    https:\/\/doi.org\/10.5551\/jat.39446\n                    \n                  .","journal-title":"J Atheroscler Thromb."},{"key":"277_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/VHRM.S95044","volume":"13","author":"N Tarantino","year":"2017","unstructured":"Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Di Biase M, Brunetti ND. Fenofibrate\/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy. Vasc Health Risk Manag. 2017;13:29\u201341. \n                    https:\/\/doi.org\/10.2147\/VHRM.S95044\n                    \n                  .","journal-title":"Vasc Health Risk Manag."},{"issue":"Suppl 1","key":"277_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0214-9168(14)70023-3","volume":"26","author":"Mijares A Hern\u00e1ndez","year":"2014","unstructured":"Hern\u00e1ndez Mijares A. Combination of pravastatin and fenofibrate (Pravafenix\u00ae). Safety studies. Clin Investig Arterioscler. 2014;26(Suppl 1):25\u201330. \n                    https:\/\/doi.org\/10.1016\/S0214-9168(14)70023-3\n                    \n                  .","journal-title":"Clin Investig Arterioscler."},{"issue":"1","key":"277_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","volume":"72","author":"M Banach","year":"2018","unstructured":"Banach M, Patti AM, Giglio RV, Cicero AF, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner \u017d, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrabl\u00edk M, Watts GF, Wong ND, Rizzo M, International Lipid Expert Panel (ILEP). The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96\u2013118. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.04.040\n                    \n                  .","journal-title":"J Am Coll Cardiol."},{"key":"277_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.phrs.2016.04.021","volume":"110","author":"M Pirro","year":"2016","unstructured":"Pirro M, Mannarino MR, Bianconi V, Simental-Mend\u00eda LE, Bagaglia F, Mannarino E, Sahebkar A. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;110:76\u201388. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2016.04.021\n                    \n                  .","journal-title":"Pharmacol Res."},{"issue":"5","key":"277_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.5114\/aoms.2017.69326","volume":"13","author":"AFG Cicero","year":"2017","unstructured":"Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner \u017d, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrabl\u00edk M, Wong ND, Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965\u20131005. \n                    https:\/\/doi.org\/10.5114\/aoms.2017.69326\n                    \n                  .","journal-title":"Arch Med Sci."},{"key":"277_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.003","volume":"24","author":"V Barrios","year":"2017","unstructured":"Barrios V, Escobar C, Cicero AF, Burke D, Fasching P, Banach M, Bruckert E. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence. Atheroscler Suppl. 2017;24:1\u201315. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2016.10.003\n                    \n                  .","journal-title":"Atheroscler Suppl."}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40292-018-0277-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-018-0277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-018-0277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:18:31Z","timestamp":1568747911000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40292-018-0277-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1007\/s40292-018-0277-9","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Dr. Cicero has spoken in Mylan SpA sponsored meetings. Other authors have no direct nor indirect conflict of interest in the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}